Eikon Therapeutics, Inc. (EIKN)

Eikon Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	104.87	129.58	112.78
Short-Term Investments	270.99	90.93	317.63
Cash & Cash Equivalents	375.85	220.51	430.41
Cash Growth	-	-48.77%	-
Other Current Assets	14.64	7.38	6.01
Total Current Assets	390.5	227.89	436.43
Property, Plant & Equipment	-	140.68	57.96
Goodwill and Intangibles	-	118.45	28.92
Other Long-Term Assets	-	4.22	2.4
Total Long-Term Assets	-	263.35	89.28
Total Assets	-	491.24	525.71
Accounts Payable	-	17.58	2.19
Current Debt	-	9.31	5.05
Other Current Liabilities	44.94	29.56	24.21
Total Current Liabilities	44.94	56.45	31.44
Long-Term Debt	-	193.15	26.69
Other Long-Term Liabilities	-	5.35	0.73
Total Long-Term Liabilities	-	198.5	27.42
Total Liabilities	-	254.95	58.86
Total Debt	247.42	202.46	31.74
Debt Growth	-	537.97%	-
Retained Earnings	-	-604.94	-361.13
Shareholders' Equity	-804.35	-571.93	-341.37
Net Cash (Debt)	128.43	18.05	398.68
Net Cash (Debt) Growth	-	-95.47%	-
Working Capital	345.56	171.44	404.99

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).